이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Arrowhead Pharmaceuticals 대차 대조표 상태
재무 상태 기준 확인 5/6
Arrowhead Pharmaceuticals 의 총 주주 지분은 $495.4M 이고 총 부채는 $280.9M, 이는 부채 대 자기자본 비율을 56.7% 로 가져옵니다. 총자산과 총부채는 각각 $955.2M 및 $459.7M 입니다.
주요 정보
56.7%
부채 비율
US$280.94m
부채
| 이자 보상 비율 | n/a |
| 현금 | US$520.91m |
| 주식 | US$495.41m |
| 총 부채 | US$459.75m |
| 총 자산 | US$955.15m |
최근 재무 상태 업데이트
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?
May 21
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth
Jun 18Recent updates
Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jun 12Arrowhead Pharmaceuticals: Hoping Something Sticks
May 27Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?
May 21Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point
May 17Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding
Apr 03Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
Mar 30Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package
Mar 08Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Feb 19Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
Jan 21Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now
Dec 25Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up
Apr 17Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now
Mar 10A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jan 24We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities
Sep 12Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming
Aug 23Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease
Aug 17Arrowhead Pharmaceuticals: An RNAi Name To Know
Jul 28Arrowhead Pharmaceuticals names internal officer as new COO
Jul 20Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs
Jul 05Arrowhead Pharma: We Can Afford To Wait For More Proof
Jun 28Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth
Jun 18Arrowhead Pharma: Know Pros' Calcs For Coming Stock Prices
Apr 14재무 상태 분석
단기부채: ARWR 의 단기 자산 ( $541.7M )이 단기 부채( $65.2M ).
장기 부채: ARWR 의 단기 자산( $541.7M )이 장기 부채( $394.6M ).
부채 대 자본 내역 및 분석
부채 수준: ARWR 총 부채보다 더 많은 현금을 보유하고 있습니다.
부채 감소: ARWR 의 부채 대 자기자본 비율은 지난 5년간 0% 에서 56.7% 로 증가했습니다.
대차 대조표
현금 런웨이 분석
과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.
안정적인 현금 활주로: ARWR 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.
예측 현금 활주로: ARWR 42.9 1.2 42.9 % 매년.